Abstract

Breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years. Metastatic breast cancer is breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body (most often the bones, lungs, liver or brain). The heterogenicity of Breast Cancer (BC) is determined by the status of human epidermal growth factor receptor 2 (HER2/neu), Estrogen Receptor (ER), and Progesterone Receptor (PR), TriplePositive BC (TPBC). Human Epidermal Growth Factor Receptor 2 (HER2) is overexpressed and/or amplified in approximately 20% of breast cancers, HER2 positivity is commonly associated with a more aggressive tumor phenotype and decreased overall survival and, moreover, with a reduced benefit from endocrine treatment. Our case is a Metastatic breast cancer with Triple positive, not response to standard protocols but she is still alive since seven years with minor complain until now.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call